| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G Arroyo, M Aldea, J Fuentealba, A G Garcí. [Nicotinic Receptor, galantamine and Alzheimer disease]. Revista de neurologia. vol 34. issue 11. 2002-12-11. PMID:12134305. |
the last approved has been galantamine that in spite of being a modest inhibitor of acetylcholinesterase, improves memory (adas cog test) and slows down cognitive impairment of alzheimer patients. |
2002-12-11 |
2023-08-12 |
Not clear |
| Hans Basun, Camilla Nilsberth, Christopher Eckman, Lars Lannfelt, Steven Younki. Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dementia and geriatric cognitive disorders. vol 14. issue 3. 2002-12-10. PMID:12218259. |
plasma levels of abeta42 and abeta40 in alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. |
2002-12-10 |
2023-08-12 |
human |
| A Desai, G Grossber. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. Expert opinion on pharmacotherapy. vol 2. issue 4. 2002-11-06. PMID:11336614. |
rivastigmine (exelontrade mark, novartis) is a novel intermediate-acting reversible and non-competitive carbamate acetylcholinesterase (ache) that was recently introduced for the treatment of alzheimer's disease (ad). |
2002-11-06 |
2023-08-12 |
Not clear |
| A Castro, A Martine. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini reviews in medicinal chemistry. vol 1. issue 3. 2002-10-30. PMID:12369973. |
peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of alzheimer's disease. |
2002-10-30 |
2023-08-12 |
Not clear |
| P Camps, D Muñoz-Torrer. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. Mini reviews in medicinal chemistry. vol 1. issue 2. 2002-10-30. PMID:12369981. |
tacrine-huperzine a hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of alzheimer's disease. |
2002-10-30 |
2023-08-12 |
Not clear |
| P Camps, D Muñoz-Torrer. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini reviews in medicinal chemistry. vol 2. issue 1. 2002-10-21. PMID:12369954. |
indeed, the only drugs currently approved for the treatment of alzheimer's disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. |
2002-10-21 |
2023-08-12 |
Not clear |
| Frances B Garfield, Denis Getsios, J Jaime Caro, Anders Wimo, Bengt Winbla. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. PharmacoEconomics. vol 20. issue 9. 2002-10-18. PMID:12141890. |
galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective in managing patients with alzheimer's disease in clinical trials. |
2002-10-18 |
2023-08-12 |
Not clear |
| Guido Rodriguez, Paolo Vitali, Caterina De Leo, Fabrizio De Carli, Nicola Girtler, Flavio Nobil. Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy. Neuropsychobiology. vol 46. issue 1. 2002-10-16. PMID:12207147. |
twenty patients affected with probable mild-to-moderate alzheimer's disease (ad; nincds-adrda criteria; 14 women and 6 men, mean age 75.2 +/- 7.1 years) who regularly received an oral acetylcholinesterase inhibitor (achei; donepezil 5 mg/day; dz group) were compared with a control group of 11 ad patients (6 women and 5 men, mean age 73.5 +/- 6.0 years) diagnosed and followed up in the pre-acheis era (c group). |
2002-10-16 |
2023-08-12 |
Not clear |
| Ho-Jin Heo, Seong-Chan Hong, Hong-Yon Cho, Bumshik Hong, Hye-Kyung Kim, Eun-Ki Kim, Dong-Hoon Shi. Inhibitory effect of zeatin, isolated from Fiatoua villosa, on acetylcholinesterase activity from PC12 cells. Molecules and cells. vol 13. issue 1. 2002-10-10. PMID:11911460. |
acetylcholinesterase (ache) inhibitors, which enhance cholinergic transmission by reducing the enzymatic degradation of acetylcholine, are the only source of the compound that is currently approved for the treatment of alzheimer's disease (ad). |
2002-10-10 |
2023-08-12 |
Not clear |
| P Tario. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert opinion on pharmacotherapy. vol 2. issue 12. 2002-09-26. PMID:11825333. |
galantamine is a newly available cholinergic drug that offsets reductions in central cholinergic neurotransmission in alzheimer's disease (ad) by specifically and reversibly inhibiting acetylcholinesterase (ache) and by allosterically modulating nicotinic cholinergic receptors. |
2002-09-26 |
2023-08-12 |
Not clear |
| Flavio Nobili, Paolo Vitali, Michela Canfora, Nicola Girtler, Caterina De Leo, Giuliano Mariani, Alberto Pupi, Guido Rodrigue. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. vol 113. issue 8. 2002-09-20. PMID:12140003. |
the recent introduction of acetylcholinesterase inhibitors (acheis) therapy for alzheimer's disease (ad) has led to the need to assess the brain's response to the therapy on an objective, neurophysiological basis. |
2002-09-20 |
2023-08-12 |
Not clear |
| J Poirie. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. International journal of clinical practice. Supplement. issue 127. 2002-09-12. PMID:12139368. |
tacrine and rivastigmine inhibit both acetylcholinesterase (ache) and butyrylcholinesterase (buche) in the csf of alzheimer's disease patients. |
2002-09-12 |
2023-08-12 |
human |
| Flavio Nobili, Malick Koulibaly, Paolo Vitali, Octave Migneco, Giuliano Mariani, Klaus Ebmeier, Alberto Pupi, Philippe H Robert, Guido Rodriguez, Jacques Darcour. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 43. issue 8. 2002-08-23. PMID:12163621. |
brain perfusion follow-up in alzheimer's patients during treatment with acetylcholinesterase inhibitors. |
2002-08-23 |
2023-08-12 |
Not clear |
| Flavio Nobili, Malick Koulibaly, Paolo Vitali, Octave Migneco, Giuliano Mariani, Klaus Ebmeier, Alberto Pupi, Philippe H Robert, Guido Rodriguez, Jacques Darcour. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. vol 43. issue 8. 2002-08-23. PMID:12163621. |
transient cognitive and behavioral stabilization of patients with alzheimer's disease (ad) is the main goal of long-term acetylcholinesterase inhibitor (achei) therapy, but response to treatment is variable and, indeed, only some of the patients are stabilized. |
2002-08-23 |
2023-08-12 |
Not clear |
| Javier Sáez-Valero, María L de Ceballos, David H Small, Carmen de Felip. Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neuroscience letters. vol 325. issue 3. 2002-08-14. PMID:12044655. |
previous studies have shown that an abnormal salt-soluble form of g(1) acetylcholinesterase (ache) is increased in the alzheimer's disease (ad) brain. |
2002-08-14 |
2023-08-12 |
rat |
| Luigia Trabace, Tommaso Cassano, Antonia Loverre, Luca Steardo, Vincenzo Cuom. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor. CNS drug reviews. vol 8. issue 1. 2002-08-09. PMID:12070526. |
chf2819 is a novel orally active acetylcholinesterase inhibitor (achei) developed for the treatment of alzheimer's disease (ad). |
2002-08-09 |
2023-08-12 |
rat |
| S Roman, N M Vivas, A Badia, M V Clo. Interaction of a new potent anticholinesterasic compound (+/-)huprine X with muscarinic receptors in rat brain. Neuroscience letters. vol 325. issue 2. 2002-08-06. PMID:12044632. |
the present results demonstrate that this acetylcholinesterase inhibitor has an ample cholinergic profile, which suggests a potential source of interest of (+/-)huprine x in alzheimer's disease therapy. |
2002-08-06 |
2023-08-12 |
rat |
| U Freo, G Pizzolato, M Dam, C Ori, L Battisti. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. Journal of neural transmission (Vienna, Austria : 1996). vol 109. issue 5-6. 2002-08-06. PMID:12111473. |
acetylcholine precursors, cholinergic agonists and acetylcholinesterase inhibitors) enhance attention and memory in experiment animals, healthy human subjects and alzheimer disease patients. |
2002-08-06 |
2023-08-12 |
human |
| U Freo, G Pizzolato, M Dam, C Ori, L Battisti. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. Journal of neural transmission (Vienna, Austria : 1996). vol 109. issue 5-6. 2002-08-06. PMID:12111473. |
in both healthy human subjects and alzheimer disease patients acetylcholinesterase inhibitors increased rcmrglc and rcbf in subcortical and cortical brain regions at rest but attenuated rcbf increases during cognitive performances. |
2002-08-06 |
2023-08-12 |
human |
| Ira T Lott, Kathryn Osann, Eric Doran, Linda Nelso. Down syndrome and Alzheimer disease: response to donepezil. Archives of neurology. vol 59. issue 7. 2002-07-26. PMID:12117361. |
individuals with down syndrome who develop alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors. |
2002-07-26 |
2023-08-12 |
Not clear |